Apr 16, 2020
SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology
Mar 23, 2020
One-Year Outcomes of Real-World RECOVER(TM) Study Published in Journal of Addiction Medicine
Dec 10, 2019
Virginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder
Dec 02, 2019
New Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes
Nov 11, 2019
Indivior Launches National Campaign Informing People of an Additional Treatment for Opioid Use Disorder (OUD) and to Let People with OUD Know That They Can "Keep Moving Towards Recovery"
Sep 26, 2019
Announcement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative
Jul 11, 2019
Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m
Jun 17, 2019
New Data from the RECOVER(TM) Study Reports on Abstinence, Drug Craving and Psychosocial Outcomes in People with Opioid Use Disorder following Transition from a Clinical Trial to the Real-World Setting
Apr 06, 2019
Indivior Announces New Study Data in Patients with Moderate to Severe Opioid Use Disorder (OUD) at the 50th ASAM Annual Conference
Apr 05, 2019
Indivior's RECOVER(TM) Study Finds Three-quarters of Patients with Moderate to Severe Opioid Use Disorder Who Received 12 monthly Injections of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection were Abstinent from Illicit Opioids One Year Later
Mar 07, 2019
The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Feb 27, 2019
Indivior Announces Launch of PERSERIS(TM) (risperidone) for the Treatment of Schizophrenia in Adults
Feb 20, 2019
Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic
Feb 19, 2019
The Lancet Publishes Phase 3 Results Demonstrating Efficacy, Safety and Tolerability of SUBLOCADE(TM) (Buprenorphine Extended-Release) Injection for Subcutaneous Use (CIII) in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Dec 20, 2018
Indivior Publishes Design and Patient Characteristics for Real-World Study of Life Changes in People Treated with SUBLOCADE(TM) (Buprenorphine Extended-Release) in Contemporary Clinical Trials
Dec 18, 2018
Indivior Provides Legal and Trading Update; Confirms Launch of PERSERIS(TM) and Key Elements of Contingency Plan
Nov 27, 2018
Indivior to Host Conference Call on December 18th; Previously-Scheduled Capital Markets Day to be Held in February 2019
Nov 23, 2018
Indivior Announces Health Canada Approval of SUBLOCADETM (Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder
Nov 01, 2018
Indivior Announces Nine Month and Third Quarter 2018 Results
Oct 24, 2018
Indivior Applauds Enactment of the SUPPORT for Patients and Communities Act of 2018